Industry News
Phase 3 trial of XTANDI™ in chemotherapy-naive patients meets both co-primary endpoints
Oct 24, 2013
Astellas Pharma Inc. and Medivation, Inc. have announced that the Independent Data Monitoring Committee (IDMC) has informed the companies of positive results from a planned interim analysis of the Phase 3 PREVAIL trial of XTANDI (enzalutamide) in more than 1,700 men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed despite androgen deprivation therapy and who have... Read More
Landmark UK-led trial shows Avastin® (bevacizumab) can prolong life in women with advanced ovarian cancer
Oct 24, 2013
New data show that Avastin improves overall survival (OS) in women with high risk advanced ovarian cancer - the deadliest gynaecological cancer in the UK2 - offering hope for thousands of women diagnosed with the disease each year. Read More
Phase 3 trial of XTANDI™ in chemotherapy-naive patients meets both co-primary endpoints
Oct 24, 2013
Astellas Pharma Inc. and Medivation, Inc... Read More
Landmark UK-led trial shows Avastin® (bevacizumab) can prolong life in women with advanced ovarian cancer
Oct 24, 2013
New data show that Avastin improves overall survival (OS) in women with high risk advanced ovarian cancer - the deadliest gynaecological cancer in the UK2 - offering hope for thousands of women diagnosed with the disease each year... Read More
Landmark UK-led trial shows Avastin® (bevacizumab) can prolong life in women with advanced ovarian cancer
Oct 24, 2013
New data show that Avastin improves overall survival (OS) in women with high risk advanced ovarian cancer - the deadliest gynaecological cancer in the UK2 - offering hope for thousands of women diagnosed with the disease each year. Read More
Phase 3 trial of XTANDI™ in chemotherapy-naive patients meets both co-primary endpoints
Oct 24, 2013
Astellas Pharma Inc. and Medivation, Inc... Read More
Landmark UK-led trial shows Avastin® (bevacizumab) can prolong life in women with advanced ovarian cancer
Oct 24, 2013
New data show that Avastin improves overall survival (OS) in women with high risk advanced ovarian cancer - the deadliest gynaecological cancer in the UK2 - offering hope for thousands of women diagnosed with the disease each year... Read More
Decision Counseling Program makes prostate cancer treatment decisions easier
Oct 24, 2013
When the pros and cons of prostate cancer treatment are spelled out using an online interactive program developed by Thomas Jefferson University researchers, more patients choose active surveillance over therapy, according to research presented Wednesday at the Society for Medical Decision Making annual meeting in Baltimore, Maryland... Read More
Older AML patients not found to benefit from sequential GO and chemotherapy
Oct 24, 2013
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more... Read More
Study points to possible treatment for brain disorders
Oct 24, 2013
Clemson University scientists are working to determine how neurons are generated, which is vital to providing treatment for neurological disorders like Tuberous Sclerosis Complex (TSC)... Read More
Previous Page Next Page